Politics & Policy

Tripping Cures

Burying a bad idea.

As congressional negotiators finalize their Medicare bill, they’ve decided to allow drug reimportation only if regulators sign off on the safety of reimported drugs. The safety issue is so serious that it is highly unlikely drug reimportation will be allowed any time soon. Thank heavens.

This is good news for Americans because the alternative–extensive reimportation–would likely have destroyed the incentives that U.S. firms have to develop new drugs. Cancer patients hoping for a new cure for their disease could abandon hope.

Such a terrible outcome would have followed because of the basic economics of the drug industry. U.S. drug firms must negotiate contracts with government monopolies in almost every developed nation. Socialized medicine allows a nation to exclude a U.S. product from its market if the U.S. firm does not make generous enough price concessions. Accordingly, what has developed is a system within which U.S. firms make large profits on new drugs in the U.S. market, but very low profits on sales everywhere else. These profit differentials show up as big differences in prices, with U.S. patients essentially subsidizing the healthcare of the rest of the world.

It certainly is annoying that French consumers pay less for many drugs than we do. But if we allow roundtrip trade, whereby a U.S. firm sells a product to France just above marginal cost and then that product is sold back to a U.S. patient at the same price, then drug firms lose their ability to profit from their successful drugs. Without profits on the winners to help offset the many drugs that go through trials and then fail, it is hard to imagine why anyone would try to develop a new drug. Reimportation would have delivered a world with very low prices for drugs that have already been discovered, and very few new discoveries.

So why did we get so close to adopting this terrible policy even though supposedly free-market ideologues control Congress? The answer is that many conservative Republicans felt reimportation might change the dynamics of price negotiations between U.S. firms and foreign governments enough so that the foreign free riders might finally pay more. Under the threat of losing their profits to imports, U.S. firms would hold the line at a higher price. If true, then reimportation might even increase the profitability of drug discovery and increase research and development.

However, our current international agreement for drug trade (the so-called TRIPS agreement) essentially handcuffs our drug companies when they negotiate with other countries. It allows a country to violate a drug patent–steal the new drug–if the country is unable to negotiate a contract at “reasonable commercial terms.” This condition may also be waived if a country declares a national emergency. In essence, the TRIPS agreement allows foreign governments to extort price concessions from drug companies.

The bottom line is that reimportation would attack our own companies rather than our strong-arming trading partners. If policymakers wish to shift the burden in paying for new drugs toward foreign patients, they should push for changes to the TRIPS agreement that put the price negotiations on a more level playing field.

Now that it appears that the bad idea is dead, let us be sure to put a stake in its heart. If we don’t, it will be certain to rise from the grave.

Kevin Hassett is a resident scholar with the American Enterprise Institute in Washington, D.C.

Kevin A. Hassett served in the Trump administration as a senior adviser and is a former chairman of the Council of Economic Advisers. He is the senior adviser to National Review's Capital Matters, a new initiative focused on financial and economic coverage.

Most Popular

Elections

Biden Is Still Underperforming Hillary

On October 20, 2016: Hillary Clinton was up 6.8 in the RealClearPolitics average in Pennsylvania. Today, Biden is up 3.8. (that race only tightened to 2.1 in the last week of 2016.) Clinton was up twelve points in Michigan on that day. Biden is up 7.5 right now. Clinton was up 6.5 in Wisconsin. Biden is ... Read More
Elections

Biden Is Still Underperforming Hillary

On October 20, 2016: Hillary Clinton was up 6.8 in the RealClearPolitics average in Pennsylvania. Today, Biden is up 3.8. (that race only tightened to 2.1 in the last week of 2016.) Clinton was up twelve points in Michigan on that day. Biden is up 7.5 right now. Clinton was up 6.5 in Wisconsin. Biden is ... Read More

Trump: No

Editor’s Note: The following is one of three essays, each from a different perspective, in the latest edition of National Review on the question of whether to vote for President Trump. The views below reflect those of the individual author, not of the NR editorial board as a whole. The other two essays can be ... Read More

Trump: No

Editor’s Note: The following is one of three essays, each from a different perspective, in the latest edition of National Review on the question of whether to vote for President Trump. The views below reflect those of the individual author, not of the NR editorial board as a whole. The other two essays can be ... Read More

Trump: Yes

Editor’s Note: The following is one of three essays, each from a different perspective, in the latest edition of National Review on the question of whether to vote for President Trump. The views below reflect those of the individual author, not of the NR editorial board as a whole. The other two essays can be ... Read More

Trump: Yes

Editor’s Note: The following is one of three essays, each from a different perspective, in the latest edition of National Review on the question of whether to vote for President Trump. The views below reflect those of the individual author, not of the NR editorial board as a whole. The other two essays can be ... Read More
Elections

How Trump Might Be Winning

I’m far too dumb to be able to shed any light on polls, but I do know something about celebrity and I think I can guarantee this: If President Trump wins re-election, Robert Cahaly is going to become very famous very quickly. Who is Robert Cahaly? The chief pollster for the Trafalgar Group, the only major ... Read More
Elections

How Trump Might Be Winning

I’m far too dumb to be able to shed any light on polls, but I do know something about celebrity and I think I can guarantee this: If President Trump wins re-election, Robert Cahaly is going to become very famous very quickly. Who is Robert Cahaly? The chief pollster for the Trafalgar Group, the only major ... Read More